Pulmonx Corporation is a medical technology company that develops and commercializes minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. The company's integrated solution consists of the Zephyr Endobronchial Valve (an implantable silicone valve deployed via bronchoscope to occlude diseased airways), the Chartis Pulmonary Assessment System (a diagnostic tool that measures collateral ventilation to identify treatment responders), and the LungTraX Platform (a cloud-based CT analysis service for patient screening and treatment planning). Pulmonx generates revenue primarily from valve and catheter sales to hospitals, with secondary income from diagnostic and imaging services, targeting interventional pulmonologists and hospital systems that treat severely symptomatic emphysema patients who have exhausted medical management options and are ineligible for or unwilling to pursue surgery.